The pharmaceutical industry has always been a hot spot for investors, and it’s no surprise that dividend stocks in this sector are highly sought after. With the constant demand for new drugs and treatments, pharmaceutical companies tend to have stable earnings and strong cash flows, making them attractive for those seeking consistent returns.
But with so many options out there, which pharma stocks should you consider for your portfolio? We’ve narrowed it down to the top 14 dividend stocks that are poised for success in 2025 and beyond.
First on our list is Pfizer, a well-known name in the industry with a dividend yield of 3.9%. With its recent acquisition of cancer drug maker Array BioPharma, Pfizer is expected to see a boost in its already impressive earnings. Next, we have Johnson & Johnson, a diversified company with a dividend yield of 2.6%. Its strong pipeline of new drugs and steady growth in other segments make it a solid choice for investors.
Another top contender is AbbVie, known for its blockbuster drug Humira. With a dividend yield of 4.9%, AbbVie is expected to continue its success with new drugs in the pipeline. And let’s not forget about Merck, which boasts a dividend yield of 3.1% and a strong portfolio of products, including the popular cancer drug Keytruda.
Other noteworthy names on our list include Eli Lilly, Bristol-Myers Squibb, and GlaxoSmithKline, all with solid dividend yields and promising developments in their pipelines. So if you’re looking to profit from the pharmaceutical industry, keep these top dividend stocks in mind for your portfolio.